Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Musculoskeletal Drugs Market Briefing 2017: Market is Expected to Reach over $165 Billion in 2020 - Research and Markets

Research and Markets
Posted on: 03 Jan 18

The "Musculoskeletal Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global musculoskeletal drugs market is expected to reach over $165 billion in 2020. This can be attributed to the expected increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, and osteoarthritis around the world. Also, increasing number of road accidents and workplace injuries are expected to contribute to market growth.

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) For Acute Musculoskeletal Pain - Topical NSAIDs are being used for treatment of acute musculoskeletal pain in adults. A NSAID penetrates the skin, enter tissues or joints, and reduce processes causing pain in the tissue. It can be used as a gel, cream, spray, or plaster to unbroken skin with musculoskeletal pain. Topical NSAIDs also leads to very low level of drug in the blood as compared to oral drugs, thus minimizing the risk of harmful effects.

In June 2015, medical research organization Cochrane published the results of its clinical trials to compare topical NSAIDs with placebo or other medicines in patients above 16 years with musculoskeletal pain. These results indicate that gel formulations of NSAIDs diclofenac and ketoprofen were more effective in treatment of strain, sprain, or muscle pull, as compared to placebo.


  • Markets Covered: Drugs For Rheumatoid Arthritis, Muscle Relaxants, Others.
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • GlaxosmithKline Plc.
  • Pfizer Inc.
  • Daiichi Sankyo Company Limited
  • Abbott Laboratories Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Celgene Corporation

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.